Meslek Yüksek Okulları / Vocational Schools

Permanent URI for this communityhttps://hdl.handle.net/11727/1410

Browse

Filters

2016 - 20192

Settings

search.filters.applied.f.publicationcategory: search.filters.publicationcategory.Makale - Uluslararası Hakemli DergiSubject: search.filters.subject.Turkey

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    HEV seroprevalence in blood donors in Turkey by two commercial total anti-HEV Ab ELISA kits
    (2019) Yasar, Osman; Karatayli, Ersin; Cengiz, Guniz; Kizilpinar, Mehtap; Yurdcu, Esra; Albayrak, Rabia; Guven, Aysel; Arslan, Onder; Karahan, Ceren; Otlu, Baris; Guducuoglu, Huseyin; Gokahmetoglu, Selma; Berk, Elife; Gitmisoglu, Ozlem; Sertoz, Ruchan; Yurdaydin, Cihan; Bozdayi, A. Mithat; Karatayli, Senem Ceren; 31403185
    Previous hepatitis E virus (HEV) seroprevalence studies in Turkey have shown high variabilities, leading to conflicting results. We aimed to re-evaluate HEV seroprevalence among blood donors in Turkey using the Wantai (Beijing, China) and the Dia.Pro (Milan, Italy) total anti-HEV antibody (Ab) enzyme-linked immunosorbent assay (ELISA) kits and compare their performances and to investigate the presence of HEV RNA in blood donors. Serum total anti-HEV antibodies were determined in a total of 2011 volunteer blood donor samples collected from different regions of Turkey (807 from Ankara, 243 from Kayseri, 284 from Izmir, 200 from Malatya, 200 from Kahramanmaras, and 277 from Van). HEV RNA was evaluated by a real-time polymerase chain reaction in a total of 272 anti-HEV seropositive samples. The country-wide HEV seroprevalence was calculated as 11.5% (Dia.Pro) and 12.2% (Wantai) with seropositivity rates of 12.0%-12.5% in Ankara, 7.4%-8.2% in Kayseri, 14.5%-15.5% in Malatya, 8.1%-8.8% in Izmir, 15.0%-16.0% in Kahramanmaras, and 12.6%-13.4% in Van by Dia.Pro and Wantai kits, respectively. The lowest detectable Ab concentrations were 0.16 and 0.14 units/mL WHO, for the Dia.Pro and the Wantai assays, respectively, showing no significant difference between assays. HEV RNA was not detected in any of the anti-HEV seropositive samples. Compared with previous studies, HEV was shown to have a higher overall seroprevalence in Turkey. Despite its limitation, the current study represents the most comprehensive HEV seroprevalence study in Turkey performed with two different commercial ELISA assays with high sensitivities so far. Further investigation is required to determine HEV genotypes in Turkey.
  • Thumbnail Image
    Item
    Analysis of the treatment costs of HIV/AIDS in Turkey
    (2016) Malhan, Simtem; Zengin, Tuba Elbir; Yenilmez, Fatma Betul; Dalgic, Canan; Cerci, Pamir; Oksuz, Ergun; Unal, Serhat; 0000-0002-5723-5965; K-8238-2012
    OBJECTIVE: Infection with the human immunodeficiency virus (HIV), the causative agent of acquired immune deficiency syndrome (AIDS), is a major global health problem. Patients with HIV can live normal lives with today's new treatment options. As the treatment is generally successful, the life expectancy of patients infected with HIV is rising. As a result, the economic burden of HIV treatment on health systems is set to increase. According to the Ministry of Health, there were more than 6000 HIV-positive patients in Turkey in 2013. The aim of this study was to determine the direct costs of HIV treatment in Turkey. METHOD: A retrospective data analysis was performed from the reimbursement agency perspective. Data for 252 patients at a university hospital in Ankara from 2001 to 2012 were used for the analysis. The average costs of treatment per HIV patient and the average costs per HIV patient, depending on the state of the patient's health, were calculated. The latter was determined according to the number of CD4 cells/ml, as defined by the CDC's classification system for HIV infection. The cost of treatment was calculated based on published reimbursement prices in 2013, per patient per year. RESULTS: The CD4 values of 25.3%, 29%, and 45.7% of the 252 patients were < 100 cells/mm(3), 100-300 cells/mm(3), and > 300 cells/mm(3), respectively. The treatment costs per patient per year for 2013 for those with CD4 values of < 100 cells/ mm(3), 100-300 cells/mm(3), and > 300+ cells/mm(3) were $ 5,637.04, $ 2,211.54, and $ 2,182.35, respectively. The weighted average of the treatment cost per patient was $ 3,344.64 for 2013. CONCLUSION: This analysis is unique to Turkey and calculates the cost only of HIV treatment in Turkey. Lower CD4 values are associated with higher treatment costs. Appropriate HIV treatment is crucial for controlling CD4 values and lowering the treatment costs of HIV patients. These findings need to be considered by policy makers who may need to focus on HIV.